Literature DB >> 23666436

Magnetic resonance spectroscopy to assess neuroinflammation and neuropathic pain.

Linda Chang1, Sody M Munsaka, Stephanie Kraft-Terry, Thomas Ernst.   

Abstract

Proton magnetic resonance spectroscopy ((1)H MRS) has been applied to numerous clinical studies, especially for neurological disorders. This technique can non-invasively evaluate brain metabolites and neurochemicals in selected brain regions and is particularly useful for assessing neuroinflammatory disorders. Neurometabolites assessed with MRS include the neuronal markers N-acetylaspartate (NAA) and glutamate (Glu), as well as the glial marker myo-inositol (MI). Therefore, the concentrations of these metabolites typically correspond to disease severity and often correlate well with clinical variables in the various brain disorders. Neuroinflammation with activated astrocytes and microglia in brain disorders are often associated with elevated MI, and to a lesser extent elevated total creatine (tCr) and choline containing compounds (Cho), which are found in higher concentrations in glia than neurons, while neuronal injury is indicated by lower than normal levels of NAA and Glu. This review summarizes the neurometabolite abnormalities found in MRS studies performed in patients with neuroinflammatory disorders or neuropathic pain, which also may be associated with neuroinflammation. These brain disorders include multiple sclerosis, neuroviral infections (including Human Immunodeficiency virus and Hepatitis C), degenerative brain disorders (including Alzheimer's disease and Parkinson's disease), stimulant abuse (including methamphetamine and cocaine) as well as several chronic pain syndromes.

Entities:  

Mesh:

Year:  2013        PMID: 23666436      PMCID: PMC3698315          DOI: 10.1007/s11481-013-9460-x

Source DB:  PubMed          Journal:  J Neuroimmune Pharmacol        ISSN: 1557-1890            Impact factor:   4.147


  114 in total

Review 1.  Neuropathological imaging: in vivo detection of glial activation as a measure of disease and adaptive change in the brain.

Authors:  Richard B Banati
Journal:  Br Med Bull       Date:  2003       Impact factor: 4.291

2.  Metabolite abnormalities in progressive multifocal leukoencephalopathy by proton magnetic resonance spectroscopy.

Authors:  L Chang; T Ernst; C Tornatore; H Aronow; R Melchor; I Walot; E Singer; M Cornford
Journal:  Neurology       Date:  1997-04       Impact factor: 9.910

3.  Brain metabolism and cognitive impairment in HIV infection: a 3-T magnetic resonance spectroscopy study.

Authors:  Mona A Mohamed; Peter B Barker; Richard L Skolasky; Ola A Selnes; Richard T Moxley; Martin G Pomper; Ned C Sacktor
Journal:  Magn Reson Imaging       Date:  2010-08-04       Impact factor: 2.546

4.  Low N-acetyl-aspartate and high choline in the anterior cingulum of recently abstinent methamphetamine-dependent subjects: a preliminary proton MRS study. Magnetic resonance spectroscopy.

Authors:  Thomas E Nordahl; Ruth Salo; Kate Possin; David R Gibson; Neil Flynn; Martin Leamon; Gantt P Galloway; Adolf Pfefferbaum; Daniel M Spielman; Elfar Adalsteinsson; Edith V Sullivan
Journal:  Psychiatry Res       Date:  2002-11-30       Impact factor: 3.222

Review 5.  Monocyte maturation, HIV susceptibility, and transmigration across the blood brain barrier are critical in HIV neuropathogenesis.

Authors:  Dionna W Williams; Eliseo A Eugenin; Tina M Calderon; Joan W Berman
Journal:  J Leukoc Biol       Date:  2012-01-06       Impact factor: 4.962

6.  Lower glutamate levels in rostral anterior cingulate of chronic cocaine users - A (1)H-MRS study using TE-averaged PRESS at 3 T with an optimized quantification strategy.

Authors:  Shaolin Yang; Betty Jo Salmeron; Thomas J Ross; Zheng-Xiong Xi; Elliot A Stein; Yihong Yang
Journal:  Psychiatry Res       Date:  2009-11-10       Impact factor: 3.222

7.  Memantine and HIV-associated cognitive impairment: a neuropsychological and proton magnetic resonance spectroscopy study.

Authors:  Giovanni Schifitto; Bradford A Navia; Constantin T Yiannoutsos; Christina M Marra; Linda Chang; Thomas Ernst; Jeffrey G Jarvik; Eric N Miller; Elyse J Singer; Ronald J Ellis; Dennis L Kolson; David Simpson; Avindra Nath; Joseph Berger; Sharon L Shriver; Linda L Millar; Dodi Colquhoun; Robert Lenkinski; R Gilberto Gonzalez; Stuart A Lipton
Journal:  AIDS       Date:  2007-09-12       Impact factor: 4.177

8.  Posterior cingulate metabolic changes occur in Parkinson's disease patients without dementia.

Authors:  R M Camicioli; J R Korzan; S L Foster; N J Fisher; D J Emery; A C Bastos; C C Hanstock
Journal:  Neurosci Lett       Date:  2004-01-16       Impact factor: 3.046

9.  MR spectroscopy indicates diffuse multiple sclerosis activity during remission.

Authors:  I I Kirov; V Patil; J S Babb; H Rusinek; J Herbert; O Gonen
Journal:  J Neurol Neurosurg Psychiatry       Date:  2009-06-21       Impact factor: 10.154

10.  Proton magnetic resonance spectroscopy of the thalamus in patients with chronic neuropathic pain after spinal cord injury.

Authors:  Pradip M Pattany; Robert P Yezierski; Eva G Widerström-Noga; Brian C Bowen; Alberto Martinez-Arizala; Bernardo R Garcia; Robert M Quencer
Journal:  AJNR Am J Neuroradiol       Date:  2002 Jun-Jul       Impact factor: 3.825

View more
  97 in total

Review 1.  The Role of Advanced Magnetic Resonance Imaging Techniques in Multiple Sclerosis Clinical Trials.

Authors:  Kedar R Mahajan; Daniel Ontaneda
Journal:  Neurotherapeutics       Date:  2017-10       Impact factor: 7.620

2.  Neurometabolites and associations with cognitive deficits in mild cognitive impairment: a magnetic resonance spectroscopy study at 7 Tesla.

Authors:  Georg Oeltzschner; S Andrea Wijtenburg; Mark Mikkelsen; Richard A E Edden; Peter B Barker; Jin Hui Joo; Jeannie-Marie S Leoutsakos; Laura M Rowland; Clifford I Workman; Gwenn S Smith
Journal:  Neurobiol Aging       Date:  2018-09-27       Impact factor: 4.673

3.  Reduced thalamic volume in preterm infants is associated with abnormal white matter metabolism independent of injury.

Authors:  Jessica L Wisnowski; Rafael C Ceschin; So Young Choi; Vincent J Schmithorst; Michael J Painter; Marvin D Nelson; Stefan Blüml; Ashok Panigrahy
Journal:  Neuroradiology       Date:  2015-02-10       Impact factor: 2.804

4.  Effects of APOE ε4, age, and HIV on glial metabolites and cognitive deficits.

Authors:  Linda Chang; Caroline Jiang; Eric Cunningham; Steven Buchthal; Vanessa Douet; Marilou Andres; Thomas Ernst
Journal:  Neurology       Date:  2014-05-21       Impact factor: 9.910

5.  Parsing the Heterogeneity of Brain Metabolic Disturbances in Autism Spectrum Disorder.

Authors:  Joseph O'Neill; Ravi Bansal; Suzanne Goh; Martina Rodie; Siddhant Sawardekar; Bradley S Peterson
Journal:  Biol Psychiatry       Date:  2019-06-21       Impact factor: 13.382

Review 6.  HIV-1 infection alters energy metabolism in the brain: Contributions to HIV-associated neurocognitive disorders.

Authors:  Bianca Cotto; Kalimuthusamy Natarajanseenivasan; Dianne Langford
Journal:  Prog Neurobiol       Date:  2019-05-18       Impact factor: 11.685

Review 7.  PET and MR imaging of neuroinflammation in hepatic encephalopathy.

Authors:  Yun Yan Su; Gui Fen Yang; Guang Ming Lu; Shawn Wu; Long Jiang Zhang
Journal:  Metab Brain Dis       Date:  2014-12-17       Impact factor: 3.584

Review 8.  In vivo imaging of neuroinflammation in schizophrenia.

Authors:  Ofer Pasternak; Marek Kubicki; Martha E Shenton
Journal:  Schizophr Res       Date:  2015-06-03       Impact factor: 4.939

Review 9.  Imaging Biomarkers of the Neuroimmune System among Substance Use Disorders: A Systematic Review.

Authors:  Eric A Woodcock; Ansel T Hillmer; Graeme F Mason; Kelly P Cosgrove
Journal:  Mol Neuropsychiatry       Date:  2019-05-09

10.  Longitudinal Metabolite Changes after Traumatic Brain Injury: A Prospective Pediatric Magnetic Resonance Spectroscopic Imaging Study.

Authors:  Barbara Holshouser; Jamie Pivonka-Jones; Joy G Nichols; Udo Oyoyo; Karen Tong; Nirmalya Ghosh; Stephen Ashwal
Journal:  J Neurotrauma       Date:  2018-12-20       Impact factor: 5.269

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.